Non-Alcoholic Steatohepatitis Biomarkers Market by Biomarkers, End Users, Trends and Forecast to 2021, Upcoming Research by iHealthcareAnalyst, Inc.

Non-alcoholic Steatohepatitis Biomarkers Market by Biomarker Type (Apoptosis Biomarkers, Hepatic Fibrosis Biomarkers, Oxidative Stress Biomarkers, Serum Biomarkers) and End User (Academics and Research Institute, Diagnostic Laboratories, Pharma and CROs, and Hospitals) and Forecast 2017-2021.

Maryland Heights, MO, May 06, 2017 --(PR.com)-- Non-alcoholic Steatohepatitis or Nonalcoholic fatty liver disease (NAFLD) is a chronic liver condition characterized by insulin resistance, type 2 diabetes and fat accumulation in the liver that may cause hepatic inflammation and progressive scarring leading to nonalcoholic steatohepatitis (NASH) and irreversible liver damage (cirrhosis). Biomarkers offer a potential prognostic or diagnostic indicator for disease manifestation, progression or both. Serum biomarkers, including total cholesterol, triglycerides, insulin resistance and C-peptide, have been used for many years. Emerging biomarkers, such as apolipoprotein A1, apolipoprotein B, leptin, adiponectin, free fatty acids, ghrelin and tumour necrosis factor-alpha, have been proposed as tools that could provide valuable complementary information to that obtained from traditional biomarkers. Moreover, markers of cell death and mitochondrial dysfunction (cytokeratins) represent powerful predictors of risk. For biomarkers to be clinically useful in accurately diagnosing and treating disorders, age-specific reference intervals that account for differences in sex and ethnic origin are a necessity.

Visit Non-alcoholic Steatohepatitis Biomarkers Market by Biomarker Type (Apoptosis Biomarkers, Hepatic Fibrosis Biomarkers, Oxidative Stress Biomarkers, Serum Biomarkers) and End User (Academics and Research Institute, Diagnostic Laboratories, Pharma and CROs, and Hospitals) and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/non-alcoholic-steatohepatitis-biomarkers-market/.

The global non-alcoholic steatohepatitis biomarkers market segmentation is based on biomarker type (apoptosis biomarkers, hepatic fibrosis biomarkers, oxidative stress biomarkers, serum biomarkers) and end user (academics and research institute, diagnostic laboratories, pharma and CROs, and hospitals).

The global non-alcoholic steatohepatitis biomarkers market report provides market size (Revenue USD Million 2014 to 2021), market share and forecasts growth trends (CAGR%, 2017 to 2021). The global non-alcoholic steatohepatitis biomarkers market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global non-alcoholic steatohepatitis biomarkers market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market and provides analysis of the company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market.

Major players operating in the global non-alcoholic steatohepatitis biomarkers market and included in this report are BioPredictive S.A.S, Exalenz Biosciences Ltd., Genfit SA, One Way Liver S.L., Prometheus Laboratories Inc. (Nestle Health Sciences), Quest Diagnostics Incorporated, Shenzhen New Industries Biomedical Engineering Co. Ltd. (SNIBE Diagnostics), and Siemens Healthcare Private Ltd. (Siemens Healthineers).

1. Biomarker Type
1.1. Apoptosis Biomarkers
1.2. Hepatic Fibrosis Biomarkers
1.3. Oxidative Stress Biomarkers
1.4. Serum Biomarkers
1.5. Others

2. End User
2.1. Academics and Research Institutes
2.2. Diagnostic Laboratories
2.3. Hospitals
2.4. Pharma and CROs

3. Geography
3.1. North America (U.S., Canada)
3.2. Latin America (Brazil, Mexico, Rest of LA)
3.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
3.4. Asia Pacific (Japan, China, India, Rest of APAC)
3.5. Rest of the World

4. Company Profile
4.1. BioPredictive S.A.S
4.2. Exalenz Biosciences Ltd.
4.3. Genfit SA
4.4. One Way Liver S.L.
4.5. Prometheus Laboratories Inc. (Nestle Health Sciences)
4.6. Quest Diagnostics Incorporated
4.7. Shenzhen New Industries Biomedical Engineering Co. Ltd. (SNIBE Diagnostics)
4.8. Siemens Healthcare Private Ltd. (Siemens Healthineers)

To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/non-alcoholic-steatohepatitis-biomarkers-market/

About Us
iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.

In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.

Contact Us
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareanalyst.com
Website: https://www.ihealthcareanalyst.com
Contact
iHealthcareAnalyst, Inc.
Ana Aitawa
(314) 500-7508
https://www.ihealthcareanalyst.com/
ContactContact
Categories